Notice: This company has been marked as potentially delisted and may not be actively trading. Oasmia Pharmaceutical AB (publ) (OASM) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends OASM vs. BTAI, ACXP, INDP, SNSE, NERV, BLRX, CSCI, IPA, MYNZ, and TXMDShould you be buying Oasmia Pharmaceutical AB (publ) stock or one of its competitors? The main competitors of Oasmia Pharmaceutical AB (publ) include BioXcel Therapeutics (BTAI), Acurx Pharmaceuticals (ACXP), Indaptus Therapeutics (INDP), Sensei Biotherapeutics (SNSE), Minerva Neurosciences (NERV), BioLineRx (BLRX), COSCIENS Biopharma (CSCI), ImmunoPrecise Antibodies (IPA), Mainz Biomed (MYNZ), and TherapeuticsMD (TXMD). These companies are all part of the "medical" sector. Oasmia Pharmaceutical AB (publ) vs. BioXcel Therapeutics Acurx Pharmaceuticals Indaptus Therapeutics Sensei Biotherapeutics Minerva Neurosciences BioLineRx COSCIENS Biopharma ImmunoPrecise Antibodies Mainz Biomed TherapeuticsMD Oasmia Pharmaceutical AB (publ) (NASDAQ:OASM) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation, community ranking and profitability. Does the MarketBeat Community favor OASM or BTAI? BioXcel Therapeutics received 119 more outperform votes than Oasmia Pharmaceutical AB (publ) when rated by MarketBeat users. Likewise, 67.49% of users gave BioXcel Therapeutics an outperform vote while only 65.97% of users gave Oasmia Pharmaceutical AB (publ) an outperform vote. CompanyUnderperformOutperformOasmia Pharmaceutical AB (publ)Outperform Votes12665.97% Underperform Votes6534.03% BioXcel TherapeuticsOutperform Votes24567.49% Underperform Votes11832.51% Which has preferable earnings and valuation, OASM or BTAI? Oasmia Pharmaceutical AB (publ) has higher earnings, but lower revenue than BioXcel Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOasmia Pharmaceutical AB (publ)$220K13.63-$18.95MN/AN/ABioXcel Therapeutics$2.28M3.42-$179.05M-$34.56-0.07 Which has more volatility & risk, OASM or BTAI? Oasmia Pharmaceutical AB (publ) has a beta of 0.96, indicating that its stock price is 4% less volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Do insiders & institutionals believe in OASM or BTAI? 0.1% of Oasmia Pharmaceutical AB (publ) shares are held by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are held by institutional investors. 21.2% of BioXcel Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Is OASM or BTAI more profitable? BioXcel Therapeutics has a net margin of -3,119.33% compared to Oasmia Pharmaceutical AB (publ)'s net margin of -8,633.64%. BioXcel Therapeutics' return on equity of 0.00% beat Oasmia Pharmaceutical AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Oasmia Pharmaceutical AB (publ)-8,633.64% -43.94% -28.92% BioXcel Therapeutics -3,119.33%N/A -105.04% Do analysts prefer OASM or BTAI? BioXcel Therapeutics has a consensus price target of $37.00, suggesting a potential upside of 1,422.63%. Given BioXcel Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe BioXcel Therapeutics is more favorable than Oasmia Pharmaceutical AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oasmia Pharmaceutical AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00BioXcel Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Does the media favor OASM or BTAI? In the previous week, BioXcel Therapeutics had 7 more articles in the media than Oasmia Pharmaceutical AB (publ). MarketBeat recorded 7 mentions for BioXcel Therapeutics and 0 mentions for Oasmia Pharmaceutical AB (publ). BioXcel Therapeutics' average media sentiment score of 0.37 beat Oasmia Pharmaceutical AB (publ)'s score of 0.00 indicating that BioXcel Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Oasmia Pharmaceutical AB (publ) Neutral BioXcel Therapeutics Neutral SummaryBioXcel Therapeutics beats Oasmia Pharmaceutical AB (publ) on 12 of the 16 factors compared between the two stocks. Remove Ads Get Oasmia Pharmaceutical AB (publ) News Delivered to You Automatically Sign up to receive the latest news and ratings for OASM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OASM vs. The Competition Export to ExcelMetricOasmia Pharmaceutical AB (publ)Pharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.00M$6.93B$5.64B$8.08BDividend YieldN/A2.71%4.89%4.04%P/E RatioN/A6.1223.7319.00Price / Sales13.63226.08381.75120.61Price / CashN/A65.6738.0534.64Price / Book0.066.656.904.26Net Income-$18.95M$139.34M$3.18B$247.00M Oasmia Pharmaceutical AB (publ) Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OASMOasmia Pharmaceutical AB (publ)N/A$0.04flatN/AN/A$3.00M$220,000.000.0057BTAIBioXcel Therapeutics3.9528 of 5 stars$3.75+73.6%$37.00+886.7%-94.7%$11.63M$2.28M-0.1190Short Interest ↑Gap UpHigh Trading VolumeACXPAcurx Pharmaceuticals2.5593 of 5 stars$0.67-5.5%$12.00+1,690.2%-83.8%$11.42MN/A-0.613Upcoming EarningsShort Interest ↑INDPIndaptus Therapeutics3.6453 of 5 stars$0.78-6.8%$8.50+987.0%-58.4%$11.04MN/A-0.466Short Interest ↓News CoverageGap UpSNSESensei Biotherapeutics4.6816 of 5 stars$0.43-7.5%$4.33+905.4%-55.7%$10.84MN/A-0.3640Short Interest ↓Positive NewsNERVMinerva Neurosciences3.5683 of 5 stars$1.53-8.4%$5.00+226.8%-44.8%$10.70MN/A-3.489Analyst ForecastShort Interest ↑High Trading VolumeBLRXBioLineRx2.2544 of 5 stars$3.16-5.7%$360.00+11,292.4%-93.1%$10.52M$21.99M-0.3640Positive NewsGap DownCSCICOSCIENS BiopharmaN/A$2.77-2.1%N/AN/A$10.46M$7.60M-0.2320Positive NewsIPAImmunoPrecise Antibodies2.2041 of 5 stars$0.33-4.1%$5.00+1,418.8%-77.2%$10.23M$24.07M-0.4280Upcoming EarningsShort Interest ↑News CoverageGap DownMYNZMainz Biomed3.0741 of 5 stars$5.07-3.1%$67.00+1,221.5%-89.0%$10.15M$917,203.00-0.0830Short Interest ↓TXMDTherapeuticsMD0.8289 of 5 stars$0.87-7.0%N/A-65.6%$9.98M$1.60M0.00420Short Interest ↑Positive News Remove Ads Related Companies and Tools Related Companies BTAI Competitors ACXP Competitors INDP Competitors SNSE Competitors NERV Competitors BLRX Competitors CSCI Competitors IPA Competitors MYNZ Competitors TXMD Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OASM) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersDOGE’s Next Move: Not what you thinkDonald Trump, Elon Musk and the Department of Government Efficiency have kept their word. Moving even faste...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Trump Orders ‘National Digital Asset Stockpile’ THIS could be the coin they choose…Crypto 101 Media | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oasmia Pharmaceutical AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Oasmia Pharmaceutical AB (publ) With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
